- Preliminary research
- Open Access
Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of 99mTc-sestamibi SPECT/CT
EJNMMI Research volume 7, Article number: 29 (2017)
Despite the progress in the quality of multiphasic CT and MRI scans, it is still difficult to fully characterize a solid kidney lesion. Approximately 10% of all solid renal tumours turn out to be oncocytomas. In actual clinical practice, this is verified only following unnecessary surgery or a renal biopsy/ablation. The objective of our pilot study examines whether 99mTc-sestamibi SPECT/CT can play a crucial role in the characterization of solid renal neoplasms and the differentiation of oncocytomas from renal cell carcinomas.
The study included 27 patients identified with 31 solid renal lesions. All patients were discussed in a multidisciplinary conference, and a decision for surgery or biopsy was taken. Prior to invasive procedures, patients underwent a SPECT/CT with 99mTc-sestamibi. Visual evaluation was performed, and any focal 99mTc-sestamibi uptake detected on SPECT in the localisation of tumour was considered as positive.
Eleven out of 12 oncocytomas (91.6%) displayed positive uptake of 99mTc-sestamibi. Three hybrid tumours (mixed-type oncocytoma and chromophobe renal cancer) were positive on SPECT/CT. One papillary renal cell carcinoma had a slight uptake of 99mTc-sestamibi. The remaining 11 renal cell carcinomas were sestamibi negative.
Differentiation of benign renal oncocytomas from renal cell carcinomas seems very promising on 99mTc-sestamibi SPECT/CT examination. Additional supplement to visual evaluation, i.e. quantitative tools, should be sought for an accurate estimate of biological behaviour and hence a secure diagnosis.
Approximately 1000 renal tumours are newly diagnosed in Sweden annually [1, 2] with 120 patients out of 250 patients within the Stockholm County being treated at Karolinska University Hospital for suspected renal cell carcinoma (RCC). RCCs account for nearly 2% of all adult cancers worldwide . The most common RCC subtypes include clear cell, papillary and chromophobe RCC accounting for 70–80%, 14–17% and 4–8% of RCCs, respectively [4, 5]. However, the number of benign renal tumours, often preoperatively misclassified as potentially malignant, is not negligible since it varies from 10 up to 20% [6, 7]. In certain studies, the percentage of benign renal lesions at surgery is even higher reaching 27% . The spectrum of benign renal lesions that can be mistaken for renal cell carcinomas encompasses renal oncocytoma, angiomyolipoma, metanephric adenoma and the infected/complicated renal cysts [8–10].
Renal oncocytomas are uncommon, but not rare tumours, since they constitute approximately 10% of all primary epithelial neoplasms of the adult kidney [11–13]. Oncocytomas can be mistaken for RCC on imaging grounds, accounting for 4–10% of nephrectomies performed for a suspected RCC . The coincidence of oncocytoma with RCC is not infrequently encountered. In addition, renal oncocytomas can be multiple in 6% and bilateral in 5% and can develop metachronic tumours in 4% of the cases .
The detection rate of solid renal lesions might have increased based on MRI/multiphasic abdominal CT, but the preoperative differentiation of oncocytoma from RCC remains a diagnostic challenge even for an experienced abdominal radiologist [16–19]. Distinct radiological features such as stellate scars, contrast uptake patterns, measurements of fat content, DWI sequences or even subtraction techniques in MRI scans cannot really resolve the diagnostic challenge in a definite way [20–22]. Those diagnostic features are not only unspecific but also directly dependent on the imaging quality of the examination scan . In addition, the diagnostic accuracy of the aforementioned imaging modalities tends to be significantly lower in tumours with a diameter of ≤20 mm .
Renal oncocytoma is a unique neoplasm given its distinct intracytoplasmic content, i.e. numerous densely packed mitochondria . Accordingly, a mitochondrial-imaging agent 99mTc-sestamibi could potentially trace oncocytomas arising in the kidneys.
Based on this hypothesis, Gormley et al. concluded in 1996 that 99mTc-sestamibi imaging appeared to play a role as a non-invasive screening method . Efforts for scintigraphic preoperative diagnosis of oncocytomas have been reported even earlier, with another imaging agent technetium 99m diethylene-triamine-pentaacetate (Tc-99m DTPA) . However, the rationale behind the use of this imaging agent with another mechanism of uptake was not strong enough to support further use of DTPA for this reason. In this context, recent work from Rowe and Gorin supported the potential role of 99mTc-sestamibi SPECT/CT in differentiating benign oncocytoma from RCC [27, 28].
Those last promising results encouraged our group to initiate this prospective pilot study by evaluating whether molecular imaging utilizing 99mTc-sestamibi SPECT/CT could reliably differentiate between oncocytomas and RCCs.
The study was initiated following approval by the Regional Ethical Review Board and the local Radiation Safety Committee. A written informed consent was acquired from all patients who participated in our study. This explorative, non-randomised prospective study started in September 2015. Patients with T1 solid renal tumours, eligible for undergoing surgery or suitable for biopsy, were included. Exclusion criteria were defined as follows: T2+ tumours, tumours >7 cm in maximum diameter and/or patients with metastatic disease. Renal impairment was not an exclusion criterion. All patients were discussed in the kidney tumour conference at the Karolinska Department of Radiology at Huddinge, in order to fully characterize the lesions and examine the operability indications.
SPECT/CT imaging was performed upon the injection of 925 ± 25 MBq 99mTc-sestamibi (produced by the National Centre for Nuclear Research, Poland; distributed by S. Ahlén Medical Nordic AB, Stockholm, Sweden), 1–4 days prior to surgical intervention or biopsy procedure.
SPECT/CT imaging was initiated 60–90 min after the injection, on a Siemens Symbia T16 (Siemens Healthcare, Erlangen, Germany) system equipped with low-energy high-resolution collimators. SPECT imaging was performed with a 128 × 128 pixel matrix size (zoom factor 1) acquiring 64 projections in a step-and-shoot mode. Each projection was acquired during a 40-s time frame.
Directly following the SPECT acquisition, a CT was performed, for the purpose of attenuation correction and anatomical correlation, using 130-kV tube voltage, 5-mm slice width and the automatic exposure control CARE Dose4D activated to provide proper tube current modulation, with a quality reference mAs setting of 10.
Reconstruction and evaluation
The SPECT and CT data were reconstructed with HERMES Hybrid Recon™ Oncology v.1.1B (HERMES Medical Solutions AB, Stockholm, Sweden). Two consultant radiologists, including an experienced nuclear medicine physician and an experienced abdominal radiologist, independently evaluated scintigraphic studies of the renal tumours without any prior knowledge of the histopathological diagnosis.
Any focal 99mTc-sestamibi uptake detected on SPECT in the localisation of known tumour detected on CT was regarded as 99mTc-sestamibi positive (sestamibi+), whereas lesions with 99mTc-sestamibi uptake lower than normal renal parenchyma were considered to be 99mTc-sestamibi negative (sestamibi−).
Confirmation of diagnosis
All lesions were biopsied/operated upon with a histopathological diagnosis eligible for analysis.
Between September 2015 and May 2016, 27 patients were included in the current study. One patient died due to other medical issues without any histopathological verification. Two patients had infected cysts that reduced in size verified on a CT control prior to surgery and therefore were not operated. In total, 24 patients were eligible for further analysis with altogether 31 solid renal tumours evaluated, since 4 patients had multiple bilateral renal lesions. Sixteen out of 31 lesions were resected whereas the rest were biopsied. The majority of the lesions had a size between 21 and 25 mm (Table 1). Despite the restrictions of SPECT/CT concerning accurate size measurements, it was easy to localize and measure the size of the kidney tumour with the help of previous CT studies that all patients had undergone.
A complete agreement was reached collaboratively between two readers in evaluating tumours visually and classifying them into sestamibi+ and sestamibi−. Our cohort study contained 12 renal lesions that turned out to be oncocytomas, 11 of which were sestamibi+ (Fig. 1) and 1 sestamibi−. The last one was verified upon resection. In total, 7 out of 12 oncocytomas were verified histopathologically upon kidney resection. Three hybrid tumours (oncocytoma and chromophobe RCC) that were also resected exhibited 99mTc-sestamibi uptake. One angiomyolipoma displayed radioisotope uptake. Among 12 RCCs (7 clear cell RCCs, 3 papillary RCCs and 2 chromophobe RCCs), 11 were clearly sestamibi− (Fig. 2). Interestingly, 1 papillary RCC verified upon resection showed a slightly elevated uptake of radiotracer.
One patient with one collision tumour (chromophobe and papillary RCC) displayed no 99mTc-sestamibi uptake. Sestamibi− included 1 lymphoma and 1 metanephric adenoma (Table 2).
99mTc-sestamibi is currently a well-established tracer for routine clinical investigations of myocardial perfusion and detection of parathyroid adenomas [29, 30]. Its mechanism of uptake is based on the tracer’s sequestration within the mitochondria of living cells, which can be applied as well on oncological imaging such as scintimammography . As oncocytomas comprise neoplastic cells filled with numerous densely packed mitochondria, 99mTc-sestamibi appears to be a suitable tracer to diagnose and differentiate this benign renal neoplasm from malignant renal tumours.
Based on tumour visual analysis, our data confirms the hypothesis that oncocytomas show uptake of 99mTc-sestamibi, which is in accordance with the aforementioned studies [25, 27, 28] with a high true positive rate. In this pilot study, 11 out of 12 oncocytomas were sestamibi+, resulting in a 91.6% sensitivity of the method. Similar high true positive rates have been reported previously from Rowe and Gorin [27, 28]. On histopathological grounds, the single oncocytoma that had no radioisotope uptake exhibited a cystic character with one third fibrous tissue. Further immunohistochemical analysis verified the oncocytic nature of the lesion according to the histopathological report.
In our study, a patient turned out to have 3 sestamibi+ solid renal tumours bilaterally. The tumours proved to be hybrid oncocytic-chromophobe tumours after resection. Similar results about the behaviour of those hybrid tumours with oncocytic components showing sestamibi uptake have been reported from Gorin et al. . Even if hybrid tumours were misdiagnosed as oncocytomas, there is no evidence of aggressive behaviour based on literature data. However, no report with a follow-up longer than 10 years has been published .
Another benign entity such as the solitary angiomyolipoma that our study includes exhibited sestamibi uptake. This behaviour, of no clinical consequence, is not in accordance with the results published from the scientific group from John Hopkins  since an angiomyolipoma was reported as sestamibi negative.
Despite the above promising results, the main clinical question arising is what should be the management of false positive lesions, i.e. sestamibi+ papillary RCC?
Papillary renal cancer with sestamibi uptake
In our pilot study of 31 renal lesions, 1 sestamibi+ tumour turned out to be a papillary RCC. This was confirmed upon nephrectomy (International Society of Urological Pathology, ISUP nucleolar grade 2). Gorin et al. report false positive results as well  due to the presence of 2 chromophobe renal tumours with sestamibi uptake.
Accordingly, a simple visual interpretation is inadequate for a secure diagnosis despite the fact that the sestamibi uptake of this papillary RCC was less intense compared to the uptake of oncocytomas and HOCTs. The false positive results raise the need of quantitative tools as an important supplement to visual evaluation. The quantitative analysis should be applied and evaluated before this method could be recommended for clinical practice.
There are clear benefits in the preoperative characterization of solid renal lesions using 99mTc-sestamibi SPECT/CT as an aid to clinical evaluation and a detailed multiphasic CT examination. Solid renal lesions without uptake of 99mTc-sestamibi on SPECT/CT have most probably a malignant character and should be the subject of surgery. Renal lesions with positive 99mTc-sestamibi uptake are probably benign in nature. Were the surgery to be avoided in these patients, it would require an estimation of the consequences regarding the risk for false positive results. Even if this risk was low, it was not negligible in our small cohort of patients. The visual interpretation could be strengthened by application of quantitative tools. This should be evaluated before applying 99mTc-sestamibi SPECT/CT in clinical routine.
Cancer i siffror. Cancerfonden och Socialstyrelsen i samarbete (in Swedish). 2013. p. 46.
Lyrdal D, Axén E, Holmberg G, et al. Laparoskopisk kirurgi vid njurtumörer [Laparoscopic surgery in kidney neoplasms]. Göteborg: Västra Götalandsregionen, Sahlgrenska Universitetssjukhuset; 2011. HTA-centrum: HTA-rapport: 37.
Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer. 2011;104:399–406.
Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135:92–109.
Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131–3.
Snyder ME, Bach A, Kattan MW, et al. Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex. J Urol. 2006;176:2391–6.
Fujii Y, Komai Y, Saito K, et al. Incidence of benign pathologic lesions at partial nephrectomy for presumed RCC renal masses: Japanese dual-center experience with 176 consecutive patients. Urology. 2008;72:598–602.
Kutikov A, Fossett LK, Ramchandani P, et al. Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology. 2006;68:737–40.
Fittschen A, Wendlik I, Oeztuerk S, et al. Prevalence of sporadic renal angiomyolipoma: a retrospective analysis of 61,389 in- and out-patients. Abdom Imaging. 2014;39:1009–13.
Lipsky MJ, Deibert CM, McKiernan JM. Epidemiology, screening and clinical staging. In: Libertino JA, editor. Renal cancer: contemporary management. New York: © Springer Science+Business Media; 2013. p. 1. doi:10.1007/978-1-4614-7236-0_1.
Cohen HT, McGovern FJ. Renal cell carcinoma. N Engl J Med. 2005;353:2477–90.
Wang Y, Hu Y, Zhai X, et al. Renal oncocytoma: a report of two cases and review of the literature. Oncol Lett. 2016;12:291–4.
Romis L, Cindolo L, Patard JJ, et al. Frequency, clinical presentation and evolution of renal oncocytomas: multicentric experience from a European database. Eur Urol. 2004;45:53–7.
Abrahams NA, Tamboli P. Oncocytic renal neoplasms: diagnostic considerations. Clin Lab Med. 2005;25:317–39.
Dechet CB, Bostwick DG, Blute ML, et al. Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma. J Urol. 1999;162:40–2.
Young JR, Margolis D, Sauk S, et al. Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT. Radiology. 2013;267(2):444–53.
Israel GM, Bosniak MA. Pitfalls in renal mass evaluation and how to avoid them. RadioGraphics. 2008;28:1325–38.
Coll DM, Smith RC. Update on radiological imaging of renal cell cancer. Journal Compilation BJU Int. 2007;99:1217–22.
Rosenkrantz AB, Hindman N, Fitzgerald EF, et al. MRI features of renal oncocytoma and chromophobe renal cell carcinoma. AJR. 2010;195:W421–7.
Kang SK, Zhang A, Pandharipande PV, et al. DWI for renal mass characterization: systematic review and meta-analysis of diagnostic test performance. AJR. 2015;205:317–24.
Kim JH, Bae JH, Lee KW, et al. Predicting the histology of small renal masses using preoperative dynamic contrast enhanced magnetic resonance imaging. Urology. 2012;80:872–6.
Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology. 2005;236:441–50.
Nakashima K, Kitagawa Y, Izumi K, et al. Diagnostic accuracy of pre-operative imaging findings in presumed clinical T1a renal cell carcinomas. Oncol Lett. 2016;11:3189–93.
Gudbjartsson T, Hardarson S, Petursdottir V, et al. Renal oncocytoma: a clinicopathological analysis of 45 consecutive cases. BJU Int. 2005;96:1275–9.
Gormley TS, Van Every MJ, Moreno AJ, et al. Renal oncocytoma: preoperative diagnosis using technetium 99m sestamibi imaging. Urology. 1996;48:33–9.
Larcos G, Forstrom LA, Mullan BP. Scintigraphic findings of renal oncocytoma. Clin Nucl Med. 1993;18:884–6.
Rowe SP, Gorin MA, Gordetsky J, et al. Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma. Clin Nucl Med. 2015;40:309–13.
Gorin MA, Rowe SP, Baras AS, et al. Prospective evaluation of 99mTc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. Eur Urol. 2016;69:413–6.
Gani MRA, Nazir F, Pawiro SA, et al. Assessment of cardiac function using myocardial perfusion imaging technique on SPECT with 99mTc sestamibi. J Phys Conf Ser. 2016;694:012057.
Hwang SH, Rhee Y, Yun M et al. Usefulness of SPECT/CT in parathyroid lesion detection in patients with thyroid parenchymal 99mTc-sestamibi retention. Nucl Med Mol Imaging. 2016; doi:10.1007/s13139-016-0438-5.
Danielsson R, Bonè B, Gad A, et al. Comparison of planar and SPECT scintimammography with 99mTc-sestamibi in the diagnosis of breast carcinoma. Acta Radiol. 1999;40:176–80.
Petersson F, Gatalica Z, Grossmann P, et al. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch. 2010;456:355–65.
The above pilot project is financially supported from VINNOVA. MIDOR study, Drn 2015-0180.
RA, OG and MK handled the conception and design of the study. AT and MK handled the data acquisition. AT and RA handled the analysis of the data. LEE, RG and OG handled the recruitment of the patients. AT, RA, MK, OG, LEE and RG handled the drafting of the manuscript. RA supervised the pilot study. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Ethics approval and consent to participate
Our pilot study is approved by the Regional Ethical Review Board and the local Radiation Safety Committee, Drn 2015/923-31/4. A written informed consent was acquired from all patients who participated in our study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.